Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 5:21 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 673–696 of 2,880 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Standard of Care Alone Clear all
Terminated Phase 2 Interventional Results available

Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205)

NCT04003610
View directory record Official record
Conditions
Metastatic Urothelial Carcinoma, Unresectable Urothelial Carcinoma
Interventions
Pemigatinib, Pembrolizumab, Gemcitabine, Carboplatin
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
13
States / cities
Greenbrae, California • Newark, Delaware • Marietta, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Oct 15, 2026, 5:21 PM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

Study of Arixtra (Fondaparinux Sodium) to Prevent Blood Clots in Women Undergoing Abdominopelvic Surgery for Likely Gynecologic Malignancy

NCT00539942
View directory record Official record
Conditions
Venous Thrombosis
Interventions
Arixtra (fondaparinux sodium), Intermittent compression devices (ICD)
Drug · Device
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years to 85 Years · Female only
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Mar 27, 2017 · Synced Oct 15, 2026, 5:21 PM EDT
Active, not recruiting Phase 2 Interventional

ChatBot and Activity Monitoring in Patients Undergoing Chemoradiotherapy

NCT05318027
View directory record Official record
Conditions
Lung Cancer, Gastrointestinal Cancer, Head and Neck Cancer
Interventions
ChatBot
Device
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Oct 15, 2026, 5:21 PM EDT
Not listed No phase listed Observational

Radiostereometric Analysis of Spine Arthrodesis

NCT01721889
View directory record Official record
Conditions
Lumbar Degenerative Disc Disease
Interventions
Radiostereometric Analysis
Radiation
Lead sponsor
OAD Orthopaedics
Other
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Warrenville, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 11, 2013 · Synced Oct 15, 2026, 5:21 PM EDT
Terminated Phase 2 Interventional Results available

Prophylactic White Cell Transfusions Versus Therapeutic White Cell Transfusions in Patients With Leukemia

NCT01204788
View directory record Official record
Conditions
Leukemia
Interventions
Prophylactic White Cell Transfusion, Therapeutic White Cell Transfusion
Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
2 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 10, 2015 · Synced Oct 15, 2026, 5:21 PM EDT
Completed Phase 1 Interventional

A Clinical Study That Will Assess the Effect of SEP-363856 and Prior Antipsychotic (PA) Standard of Care on Glucose and Regulation of Insulin in Patients With Schizophrenia

NCT05463770
View directory record Official record
Conditions
Schizophrenia
Interventions
SEP-363856
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
8
States / cities
Little Rock, Arkansas • Rogers, Arkansas • Long Beach, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2024 · Synced Oct 15, 2026, 5:21 PM EDT
Active, not recruiting Phase 2 Interventional

Zanubrutinib and CAR T-cell Therapy for the Treatment of Recurrent or Refractory Aggressive B-cell Non-Hodgkin's Lymphoma or Transformed Indolent B-cell Lymphoma

NCT05202782
View directory record Official record
Conditions
Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation, EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma, Not Otherwise Specified, Large B-Cell Lymphoma With IRF4 Rearrangement, Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, Recurrent Aggressive B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, Recurrent Intravascular Large B-Cell Lymphoma, Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Recurrent T-Cell/Histiocyte-Rich Large B-Cell Lymphoma, Recurrent Transformed B-Cell Non-Hodgkin Lymphoma, Refractory Aggressive B-Cell Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, Refractory Intravascular Large B-Cell Lymphoma, Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Refractory T-Cell/Histiocyte-Rich Large B-Cell Lymphoma, Refractory Transformed B-Cell Non-Hodgkin Lymphoma
Interventions
Chimeric Antigen Receptor T-Cell Therapy, Quality-of-Life Assessment, Questionnaire Administration, Zanubrutinib
Biological · Other · Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
2
States / cities
Chicago, Illinois • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 16, 2024 · Synced Oct 15, 2026, 5:21 PM EDT
Not listed Not applicable Interventional

STIMFIX Trail Lead Anchor System for Dorsal Column Stimulator Trail Leads (SECURE Study)

NCT05651646
View directory record Official record
Conditions
Pain
Interventions
Intervention Arm (STIMFIX)
Other
Lead sponsor
STIMFIX
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
3
States / cities
Lake Havasu City, Arizona • Los Angeles, California • Clifton, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 15, 2022 · Synced Oct 15, 2026, 5:21 PM EDT
Recruiting Not applicable Interventional

A Pilot Project to Facilitate Dental Care and Reduce Barriers For Youth With Disabilities

NCT06710483
View directory record Official record
Conditions
Intellectual Disability, Variable
Interventions
Pre-Dental Telehealth (PDT)
Behavioral
Lead sponsor
Boston University
Other
Eligibility
12 Years to 18 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 15, 2026, 5:21 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Using Connected Health to Increase Lung Cancer Screening

NCT04612946
View directory record Official record
Conditions
Lung Cancer
Interventions
Referral to Telemedicine LCS Counseling Visit, Usual Care
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
55 Years to 77 Years
Enrollment
137 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 7, 2022 · Synced Oct 15, 2026, 5:21 PM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Single Dose Aminoglycosides for Acute Uncomplicated Cystitis in the Emergency Department Setting

NCT05702762
View directory record Official record
Conditions
Urinary Tract Infections
Interventions
Gentamicin, Standard of Care
Drug
Lead sponsor
Mercy Health Ohio
Other
Eligibility
18 Years and older · Female only
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Youngstown, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 27, 2023 · Synced Oct 15, 2026, 5:21 PM EDT
Completed Not applicable Interventional

Intermittent Pneumatic Compression of the Thigh

NCT05659394
View directory record Official record
Conditions
Venous Leg Ulcer
Interventions
Standard Wound Care Alone, Stand Wound Care plus IPC
Other · Device
Lead sponsor
Huntleigh Healthcare Ltd
Industry
Eligibility
Not listed
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
5
States / cities
Hollywood, Florida • North Port, Florida • Tulsa, Oklahoma + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2024 · Synced Oct 15, 2026, 5:21 PM EDT
Terminated Phase 2 Interventional

Safety Study of Cervical Sympathetic Block for Cerebral Vasospasm Following Aneurysmal Subarachnoid Hemorrhage

NCT00930072
View directory record Official record
Conditions
Vasospasm
Interventions
Cervical Sympathetic Block (bupivicaine, clonidine)
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 27, 2017 · Synced Oct 15, 2026, 5:21 PM EDT
Active, not recruiting Not applicable Interventional

Safety and Efficacy of Ketogenic Diet for Promoting Weight Loss in Obese Individuals With Compensated NASH Cirrhosis

NCT04383951
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis, Cirrhosis, Liver
Interventions
Dietary consult for participants in the ketogenic diet arm, Dietary consult for participants in the standard of care arm
Other
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 17, 2026 · Synced Oct 15, 2026, 5:21 PM EDT
Recruiting No phase listed Observational

Safety Study to Evaluate the Occurrence of EFAD in Pediatric Patients With PNAC Who Require More Than Eight Weeks of Omegaven Treatment

NCT06274788
View directory record Official record
Conditions
Parenteral Nutrition Associated Liver Disease (PNALD), Essential Fatty Acid Deficiency, Malnutrition, Pediatric ALL
Interventions
Omegaven® (fish oil triglycerides) Injectable Emulsion
Drug
Lead sponsor
Fresenius Kabi
Industry
Eligibility
1 Day to 17 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
10
States / cities
Fountain Valley, California • Los Angeles, California • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 15, 2026, 5:21 PM EDT
Active, not recruiting Phase 3 Interventional

An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

NCT04720157
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
177Lu-PSMA-617, 68Ga-PSMA-11, ARDT, ADT
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years · Male only
Enrollment
1,140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
70
States / cities
Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 50 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Oct 15, 2026, 5:21 PM EDT
Terminated Phase 3 Interventional

Study of Human Monoclonal Antibody to Treat Mycosis Fungoides and Sezary Syndrome

NCT00127881
View directory record Official record
Conditions
Mycosis Fungoides, Sezary Syndrome
Interventions
HuMax-CD4 (zanolimumab)
Drug
Lead sponsor
Emergent Product Development Seattle LLC
Industry
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
19
States / cities
Birmingham, Alabama • Stanford, California • Aurora, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2012 · Synced Oct 15, 2026, 5:21 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Dose Escalation, Expansion Study of Vofatamab (B-701) in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma

NCT02401542
View directory record Official record
Conditions
Locally Advanced or Metastatic Urothelial Cell Carcinoma, Urinary Bladder Disease, Urological Diseases
Interventions
Vofatamab, Docetaxel, Placebo
Drug
Lead sponsor
Rainier Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
11
States / cities
Gilbert, Arizona • Goodyear, Arizona • Duarte, California + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2020 · Synced Oct 15, 2026, 5:21 PM EDT
Terminated Phase 2 Interventional Results available

StrataGraft® Skin Tissue as an Alternative to Autografting Full-thickness Complex Skin Defects

NCT03005054
View directory record Official record
Conditions
Trauma-related Wound, Burns, Skin Wound
Interventions
StrataGraft Skin Tissue, Autograft
Biological · Procedure
Lead sponsor
Stratatech, a Mallinckrodt Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
4
States / cities
Phoenix, Arizona • Winston-Salem, North Carolina • Fort Sam Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2021 · Synced Oct 15, 2026, 5:21 PM EDT
Completed Not applicable Interventional

Telehealth Intervention for Improved Blood Pressure Control With Targeted Incentives

NCT04075045
View directory record Official record
Conditions
Hypertension, Non-Adherence, Patient
Interventions
Wellth Smartphone App, Targeted Incentives, Non-Restricted Incentives
Behavioral
Lead sponsor
Wellth Inc.
Industry
Eligibility
50 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
3
States / cities
San Diego, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 22, 2020 · Synced Oct 15, 2026, 5:21 PM EDT
Terminated Phase 2 Interventional

Phase II of AUY922 in Second-line Gastric Cancer in Combination With Trastuzumab in HER2 Positive Patients

NCT01402401
View directory record Official record
Conditions
Advanced Gastric Cancer
Interventions
AUY922, Trastuzumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
3
States / cities
Los Angeles, California • Lake Success, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 10, 2020 · Synced Oct 15, 2026, 5:21 PM EDT
Enrolling by invitation Not applicable Interventional

Examining the Impact of a Digital Health Program and TENS Device for Patients With Chronic Low Back Pain

NCT07011537
View directory record Official record
Conditions
Back Pain Lower Back Chronic, Chronic Pain, Musculoskeletal Pain
Interventions
Digital Musculoskeletal (MSK) Program, Transcutaneous Electrical Nerve Stimulation (TENS), Standard of Care (SOC)
Behavioral · Device · Other
Lead sponsor
Hinge Health, Inc
Industry
Eligibility
18 Years and older
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Eden Prairie, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 23, 2026 · Synced Oct 15, 2026, 5:21 PM EDT
Completed Not applicable Interventional

SDRM® vs. Collagen for Diabetic Foot Ulcers

NCT05883098
View directory record Official record
Conditions
Diabetic Foot, Ulcer Foot, Wound Heal
Interventions
Wound debridement, Wound closure matrix application
Procedure · Device
Lead sponsor
Polymedics Innovations Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Circleville, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 28, 2023 · Synced Oct 15, 2026, 5:21 PM EDT
Terminated Not applicable Interventional Results available

Capsular Tension Rings in Intraocular Lens Rotation

NCT04436198
View directory record Official record
Conditions
Cataract, Ophthalmoplegia, Ophthalmologic Complication
Interventions
MORCHER® EYEJET® CTR Types 14, 14A, and 14C, Toric IOL Only
Device
Lead sponsor
Rachel Lieberman
Federal
Eligibility
30 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Nellis Air Force Base, Nevada
Source: ClinicalTrials.gov public record
Updated Aug 19, 2024 · Synced Oct 15, 2026, 5:21 PM EDT